Elutia Inc. Class A Common Stock

Day range

$0.79 – $0.88

Open

$0.85

Prev close

$0.88

Volume

50.44K

Market cap

$39.02M

Shares out

44.29M

P/E

0.72

P/S

3.93

P/B

2.55

P/FCF

—

ROE

354.9%

ROA

112.9%

Debt/Equity

0.53

Div yield

0.00%

As of Nov 12, 2026

• Quarterly earningsNov 5, 2026

  On November 5, 2026, Elutia Inc. (the "Company" or "Elutia") issued a press release announcing its results for the third quarter ended September 30, 2026.

• Credit facilityAug 21, 2026

  Also in connection with the completion of the sale of the SimpliDerm Business assets, the Company amended its Loan and Security Agreement dated August 11, 2026 with Avenue Venture Opportunities Fund II, L.P., as agent, and the lenders party thereto, to release the lien on the assets.

• Listing deficiency noticeAug 7, 2026

  On August 6, 2026, Elutia Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's Class A common stock was below $1.00 per share, which is the minimum closing bid price required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Company was provided a compliance period of 180 calendar days from the date of the Notice, or until February 2, 2027, to regain compliance with the Minimum Bid Price requirement.

• Business line exitJul 20, 2026

  The assets of the SimpliDerm Business constitute substantially all of the assets currently held in Elutia's Women's Health segment. Cellution Biologics will purchase from the Company substantially all of the assets related to the Company's business of commercializing, manufacturing, distributing, selling and/or marketing human acellular dermis (hADM) products for use in the field of breast reconstruction under the SimpliDerm® brand.

• Equity compensation grantJun 16, 2026

  The First Amendment: (i) increased the number of shares authorized for issuance of awards under the 2020 Plan by an additional 3,000,000 shares of the Company's Class A common stock; (2) extended the annual increase of shares of the Company's Class A common stock authorized under the 2020 Plan through January 1, 2036 (the tenth January 1 after the Amendment Date); and (3) extended the termination date of the 2020 Plan to the tenth anniversary of the Amendment Date.

Days to cover

1.0

Short interest

33.66K

Avg volume

70.79K

As of Oct 30, 2026 · reported to FINRA twice monthly.

• Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
  neutralGlobeNewswire Inc.· Mar 13, 2026
• Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
  positiveBenzinga· Oct 1, 2025
• Zacks.com featured highlights BRC, Costamare and Elutia
  Zacks Investment Research· Jun 27, 2024
• 3 Best Breakout Stocks Worth a Buy for Attractive Returns
  Zacks Investment Research· Jun 26, 2024
• Elutia Announces $13.26 Million Registered Direct Offering
  GlobeNewswire Inc.· Jun 17, 2024